Human CD19 Soluble Biomarker in CNS to detection of leptomeningeal lymphoma by flow Cytometry.

Increased levels of soluble CD19 protein (sCD19) in the Cerebrospinal Fluid (CSF) are associated with a higher risk of central nervous system (CSN) lymphoma in B-LNH patients. Flow cytometry (FCM) detection of lymphoma cells plays an important role for identification of CNS disease, and the possibility to measure sCD19 levels by FCM may contribute to establish a more accurate diagnosis.. Despite this suitable approach, there is not available any commercial assay for measure of sCD19 levels in CSF by FCM. In this sense, we are developing a bead based immunoassay to address this issue, for more accurate identification of CNS disease in B-NHL patients.